COMPANY PROFILE

CoBX Bio

Explore full profile

Covalent therapies and drug discovery platform

Seoul, South KoreaFounded 2024Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Total funding $10–50M Disclosed equity funding

Unlock exact values

About CoBX Bio

CoBX Bio is a South Korean drug development company founded in 2024 by Choi Hwan-geun, Kim Nam-doo, and Son Jeong-beom. The company is focused on researching and developing covalent bond inhibitors and molecular adhesive degraders to address the shortcomings of existing synthetic medications, such as drug resistance and insufficient effectiveness.

The company's core technology is its proprietary RaPIDome platform, which integrates chemical proteomics, molecular modeling, and AI to identify drug mechanisms and resistance pathways. CoBX Bio's main product pipelines include covalent inhibitors that target Menin, a protein derived from the MEN1 gene, and molecular adhesive degraders aimed at GSPT1, a protein associated with the survival of cancer cells. These compounds are engineered to form stronger attachments to disease-related proteins, aiming for enhanced efficacy and the ability to mitigate resistance.

In September 2025, CoBX Bio secured KRW 7.6 billion (approximately $5.47M) in a pre-Series A funding round from a consortium of investors including Korea Investment Partners, Laplace Partners, Solidus Investment, Company K Partners, KB Investment, and UTC Investment. The company operates in the biopharmaceuticals, bioinformatics, and pharmaceutical research and development sectors and is currently in an early, pre-clinical stage of development.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2024
Headquarters: Seoul, South Korea
Open positions: None listed
Dealroom signal: 21.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Biomarkers, Chronic Disease
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jul 2026	$24M	$98M	Forest Ventures · Korea Investment Partners · Atinum Investment · KB Investment	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

CoBX Bio website traffic

Latest recorded traffic for CoBX Bio is 1.2K monthly website visits, up 5900% over the last three months.

Latest monthly visits1.2K 3-month web change+5900%

Monthly website visitsFeb 2026–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SESequantrixAI-driven fibrosis target discovery and drug development	Aachen, Germany	Operational	12	—	—
NMNOBO MedicineBiomarker-driven targeted therapies for oncology and chronic diseases	Seoul, South Korea	Operational
TBTakis BiotechInvolved in the identification of new biomarkers and in the development of molecular diagnostic tests	Rome, Italy	Operational
LHLG HealthVenture fund accelerating precision medicine and healthcare innovation.	—	Operational
CVCereNexis VenturesOperator-led learning engine for healthcare innovation.	—	Operational
SISafeLane Health, IncHealth Tech & Medtech	—	Operational
ABAmbrosia BiotherapeuticsOral small-molecule therapies for obesity and metabolic disorders	Half Moon Bay, United States	Operational
OTOTR TherapeuticsAccelerating preclinical assets into differentiated clinical therapies	China	Operational